Argus Research analyst John Eade maintains Novo Nordisk (NYSE:NVO) with a Buy and raises the price target from $125 to $160.
Argus Research Maintains Buy on Novo Nordisk, Raises Price Target to $160
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.